Evidence map›Paper›PMID 41907685›Full record

ArticleTherapeutic advances in musculoskeletal disease2026

The protocol for a patient-driven online prospective European observational cohort aiming to determine risk factors for the development of psoriatic arthritis among people living with psoriasis: the HIPPOCRATES Prospective Observational Study.

Teresa Grohmann, Timeo Mtenga, David Kerr, Joe Barrett, Nathanael Gray, Heidi Bertheussen, Juan D Cañete, Kurt de Vlam, Maarten de Wit, Theodoros Dimitroulas and 26 more

Registry-linked trialAbstract read
In one paragraph

Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05858528 (Determining Risk Factors for the Development of Psoriatic Arthritis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05858528 recruitingnot on this map

Determining Risk Factors for the Development of Psoriatic Arthritis (PsA) Amongst People Living With Psoriasis: A Patient-driven On-line Prospective European Observational Cohort

TypeobservationalSponsorUniversity of OxfordRan2023 to 2026Enrolled25,000ConditionsPsoriatic Arthritis, PsoriasisArmsPEST screening questionnaire
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Teresa GrohmannConway Institute, School of Medicine, University College Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0003-2952-6201
Timeo MtengaNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
David KerrNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Joe BarrettNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Nathanael GrayNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Heidi BertheussenHIPPOCRATES Patient Research Partner, Oslo, Norway.
Juan D CañeteHospital Clinic de Barcelona and IDIBAPS, Barcelona, Spain.
Kurt de VlamDivision of Rheumatology, UZ Leuven, Leuven, Belgium.
Maarten de WitHIPPOCRATES Patient Research Partner, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-8428-6354
Theodoros DimitroulasFourth Department of Internal Medicine, Hippokration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Sam GroothuizenDepartment of Rheumatology and Clinical Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0009-0007-6097-8886
Glenn HaugebergDivision of Rheumatology, Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway.
Mari HoffDepartment of Neuromedicine and Movement Science, NTNU-Norwegian University of Science and Technology, Trondheim, Norway.
Rudolf HorváthDepartment of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia.ORCID https://orcid.org/0000-0001-5787-9990
Jana HurnakovaDepartment of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia.
Michaela KoehmRheumatology, Immunology-Inflammation Medicine, Goethe-University Frankfurt, Frankfurt, Germany.
Przemyslaw KotylaDepartment of Rheumatology and Clinical Immunology, Voivodeship Hospital No. 5, Sosnowiec, Poland.
Jean-Guillaume LetarouillyService de Rhumatologie, CHU de Lille, Université de Lille, Lille, France.ORCID https://orcid.org/0000-0003-2793-6303
Rik LoriesDivision of Rheumatology, UZ Leuven, Leuven, Belgium.
Mari LøsetHUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
Christine MöserFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany.ORCID https://orcid.org/0009-0006-8773-629X
Burkhard MöllerDepartment of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Maria MytilinaiouFourth Department of Internal Medicine, Hippokration Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Mikkel ØstergaardCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.
Ana RodriguesComprehensive Health Research Centre, NOVA Medical School, NOVA University, Lisbon, Portugal.
Caitriona RyanCharles Institute of Dermatology, University College Dublin, Dublin, Ireland.
Carlo SelmiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Liv EidsmoDivision of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Axel SvedbomUnit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Tiago TorresDepartment of Dermatology, Centro Académico Clínico, ICBAS-Santo António, University of Porto, Porto, Portugal.
Florentin Ananu VrejuDepartment of Rheumatology, University of Medicine and Pharmacy Craiova, Craiova, Romania.
Marleen G H van de SandeDepartment of Rheumatology and Clinical Immunology, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Lars WernerHIPPOCRATES Patient Research Partner, Copenhagen, Denmark.
Stephen R PenningtonUCD Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0001-7529-1015
Oliver FitzGeraldConway Institute for Biomolecular Research, School of Medicine, University College Dublin, Dublin, Ireland.ORCID https://orcid.org/0000-0002-6607-6070
Laura C CoatesBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford OX3 7LD, UK.ORCID https://orcid.org/0000-0002-4756-663X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Up to one-third of people living with psoriasis develop psoriatic arthritis (PsA), and the majority have active psoriasis prior to the development of arthritis. Clinical risk factors, such as nail involvement, in conjunction with novel blood biomarkers, could improve PsA risk monitoring and early diagnosis. Objectives: The aim of the HIPPOCRATES Prospective Observational Study (HPOS-www.hpos.study) is to follow a cohort living with psoriasis and identify risk factors for the development of PsA. Design: HPOS is a patient-driven online prospective European observational cohort. Methods: Adult participants with psoriasis but with no prior diagnosis of PsA are eligible. Participants are invited to provide consent and join the study online. They complete a semi-structured questionnaire to collect data on demographics, psoriasis, comorbidities, risk factors for PsA, and the Psoriasis Epidemiology Screening Tool screening questionnaire. Follow-up is conducted through a questionnaire every 6 months. The primary outcome is the new onset of PsA confirmed by a diagnosis from their doctor. The study will also collect peripheral blood samples from a subset of participants for biomarker identification. Ethics: This study follows the principles of the Declaration of Helsinki. To date, ethical approval has been granted by independent ethical committees in 10 countries. Discussion: Studying a cohort of individuals with psoriasis will allow us to identify risk factors for arthritis development and to develop a risk calculator. This can support focused efforts on screening, patient education, and even studies looking to delay or prevent the onset of arthritis. This study, run via remote online data collection, provides an efficient way to recruit a large cohort (25,000) across multiple countries. However, challenges have had to be addressed with some key changes in study design, ethical review, and recruitment strategies required for each individual country. Trial registration: HPOS, Clinicaltrials.gov ID: NCT05858528, IRAS number 325080; https://clinicaltrials.gov/study/NCT05858528?locStr=United%20Kingdom&country=United%20Kingdom&cond=Psoriasis&term=HPOS&aggFilters=status%3Anot%20rec&rank=1.

Indexed as

biomarkersHIPPOCRATESpredictionpsoriasispsoriatic arthritisrisk factors

Identifiers

PMID41907685
PMCPMC13018678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.